Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company’s lead product candidate, will be presented in eight poster presentations at the Neuroscience Education Institute (NEI) Congress.
| CORAL GABLES, Fla., Oct. 29, 2021 /PRNewswire/ -- Relmada Therapeutics Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company’s lead product candidate, will be presented in eight poster presentations at the Neuroscience Education Institute (NEI) Congress. The poster session will be held in-person and virtually on Friday, November 5, 2021, from 4:00 to 5:30 PM MST in Colorado Springs, CO. In addition, Relmada is hosting an interactive exhibit booth both in-person and virtually. Additional details provided below:
Participation:
Posters Presented: Title: REL-1017 (esmethadone; d-methadone) as Adjunctive Treatment in Patients with Major Depressive Disorder: A Phase 2a Double-Blind Randomized Trial. Title: A Phase 2a Double-Blind Randomized Trial of REL-1017 (esmethadone) in Patients with Major Depressive Disorder: Analysis of Subscales from the Symptoms of Depression Questionnaire. Title: Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder. Title: No Meaningful Opioid Abuse Liability of REL-1017 (esmethadone; d-methadone), a Rapid-acting Antidepressant in Clinical Development: a Human Abuse Potential Study. Title: REL-1017 (esmethadone; d-methadone): Assessment of Reinforcement-type Behavior, Physical Dependence, and Withdrawal in Sprague Dawley Rats. Title: Effect of REL-1017 (esmethadone; d-methadone) on Cholesterol, Triglycerides, PCSK9 and hs-CRP in Patients with Major Depressive Disorder. Title: Characterization of Esmethadone and Other NMDAR Channel Blockers on Human Heterodimeric N-methyl-D-aspartate Receptors. Title: REL-1017 (esmethadone; d-methadone) Did Not Produce Initial or Cumulative Neurotoxic Effects or Other Evidence of Damage to Cortical Neurons in Sprague Dawley Rats Exhibit in-person participation: Booth #803
Online simulcast link will be available on virtual conference platform to registered virtual attendees About REL-1017 REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD in adjunctive and monotherapy Phase 3 studies. The ongoing RELIANCE Phase 3 Clinical Research Program is designed to evaluate the potential for REL-1017 as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust and sustained antidepressant effects with statistically significant improvements compared to placebo in all tested measures of depression. The Phase 2 study also confirmed the favorable safety, tolerability and pharmacokinetics profile of REL-1017 observed in previously completed Phase 1 studies. About Relmada Therapeutics, Inc. Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com. Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Relmada or on its behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding Relmada’s plans to develop REL-1017; and expectations related to trials evaluating REL-1017 and potential regulatory approval of REL-1017, including those related to feedback from the FDA. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading “Risk Factors” set forth in Relmada’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list. Investor Contact: Media Inquiries:
SOURCE Relmada Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:RLMD |
View original content to download multimedia:
